The study is evaluating Abraxane administered as adjuvant therapy following Adriamycin (A) plus Cytoxan (C) in early stage breast cancer. Adjuvant treatment is given after primary therapy (often
The new Kaletra (lopinavir/ritonavir) tablet was developed using a proprietary novel melt-extrusion technology intended to allow patients to take fewer tablets per dose as part of their treatment
The Biopharma operations will be fully integrated with the core pharmaceutical R&D organization of Schering-Plough to help maintain an efficient overall product flow process. Schering-Plough has been maintaining
The study is one of a continuing series evaluating Evizon (squalamine lactate) for the treatment of choroidal neovascularization associated with age-related macular degeneration (AMD), also known as “wet”
Exjade has already been granted fast-track status in the US and Switzerland. Priority review has been requested in the US. The treatment has also received Orphan Drug status
ImVision focuses on the development of novel immunotherapeutics based on its proprietary MAT (Modular-Antigen-Transport) technology to treat allergic diseases, chronic infectious diseases and possibly cancer. The technology, developed
PharmaFrontiers has a history of developing autologous cellular therapies for the treatment of multiple sclerosis and is currently moving into phase II clinical trials with its novel therapy
Prostate cancer is the most common cancer diagnosis in men other than skin cancer. Despite hormone treatment the disease resurfaces in many patients. When this occurs the patient
The application is based on data from two randomized, multicenter, investigator-blinded clinical trials comparing INKP-102 to Visicol tablets, InKline’s current sodium phosphate treatment. Both a phase II dose-ranging
The company has closed a $40 million round of private equity financing, with participation from several leading venture capital firms, to support its expanding research and product development
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.